What was recalled
The U.S. Food and Drug Administration (FDA) has announced a Class II recall involving medical devices manufactured by Bayer Medical Care, Inc. This action centers specifically on the MEDRAD Stellant FLEX Syringe Kit, which is designed to be used in conjunction with the Stellant FLEX CT Injection System. To understand exactly what is affected, it is important to look at the precise identifiers that distinguish these kits from other medical supplies. The recall applies strictly to the unit catalog number FLEXS-150-QFT. Within this specific catalog designation, the issue is limited to items bearing the unique device identifier (UDI-DI) 00616258022895. Furthermore, the affected inventory is tied to a specific material number, identified as 87078825, and one particular batch number, 8688750. If you are trying to determine whether a specific kit in your possession is part of this recall, these numbers are the critical details you must verify against your records.
The scope of this distribution was nationwide, reaching medical facilities across all fifty states within the United States. The geographic origin associated with this specific recall event is Pennsylvania, where Bayer Medical Care operates. It is important to note that while the brand is Bayer Medical Care, the product itself is a specialized component for computed tomography (CT) scanning procedures. These syringe kits are not consumer goods sold in retail stores; they are professional-grade medical supplies distributed to healthcare providers who utilize the Stellant FLEX CT Injection System to administer contrast media during imaging studies. The distribution pattern indicates that these specific units were widely available to medical institutions throughout the country, rather than being limited to a single region or hospital system.
The recall was officially initiated on July 31, 2026. At the time of this announcement, the FDA classified this as a Class II recall. In regulatory terms, a Class II classification suggests that the defect is not likely to cause serious adverse health consequences or death, but it may result in temporary medical problems or require corrective action. This classification underscores the importance of identifying and removing these specific units from clinical use to ensure patient safety standards are maintained. The lack of a stated remedy in the initial recall notice means that healthcare providers must contact Bayer Medical Care directly for further instructions on how to handle the affected inventory, including potential returns or replacements.
Understanding the specifics of this recall helps medical professionals quickly isolate the problem. Because the issue is tied to a single batch number (8688750) and material number (87078825), it does not imply that all MEDRAD Stellant FLEX Syringe Kits are defective. Only those produced under the specific conditions associated with this batch are at risk. This precision allows hospitals and imaging centers to audit their current stock without halting all CT injection procedures unnecessarily. By focusing on the catalog number, UDI-DI, material number, and batch number, providers can efficiently identify the affected kits and take appropriate action.
The hazard, explained
When we talk about a medical device recall due to sterilization failures, it is important to understand that the danger is not always immediate or visible. In this specific case involving the Bayer Medical Care MEDRAD Stellant FLEX Syringe Kit (Catalog Number: FLEXS-150-QFT), the core issue is that some units may not have been properly sterilized during the manufacturing process. This means that microscopic life forms—such as bacteria, viruses, or fungi—that should have been eliminated are still present on the device surfaces. Because these syringes are designed to be used in conjunction with the Stellant FLEX CT Injection System for medical procedures, they are intended to come into direct contact with a patient’s bloodstream or internal tissues. When a non-sterile device enters that environment, it bypasses the body’s natural external defenses, creating a direct pathway for infection.
The mechanism of harm here is straightforward but serious: introduction of pathogens. Normally, medical equipment undergoes rigorous sterilization processes, such as ethylene oxide gas treatment or radiation, to ensure all biological contaminants are destroyed. When that process fails, even if the device looks clean and functions mechanically without issue, it becomes a vehicle for disease. If these contaminated syringes are used in CT imaging procedures where contrast media is injected into veins, any surviving microbes can enter the circulatory system directly. This can lead to local infections at the injection site or, more critically, systemic infections like bacteremia (blood poisoning) or sepsis. These conditions can escalate quickly, requiring hospitalization, intravenous antibiotics, and in severe cases, intensive care.
It is crucial to note that you cannot tell if a device is non-sterile by looking at it. The packaging may appear intact, the expiration date might still be valid, and the syringe itself may look perfectly clean and functional. Sterility is a microscopic state, not a visual one. This is why regulatory agencies like the FDA issue these recalls proactively based on manufacturing quality control data rather than waiting for patients to fall ill. The risk is inherent to the batch produced under specific conditions—here linked to Affected Material Number 87078825 and Batch Number 8688750—and affects units distributed nationwide from Pennsylvania. Understanding this helps clarify why immediate action is necessary: the hazard is silent, but its consequences can be profound.
Who is most at risk
To understand who faces the greatest potential impact from this recall, we first need to look at who actually handles or interacts with these devices in a clinical setting. The recalled product is the MEDRAD® Stellant FLEX Syringe Kit, which is designed specifically for use with the Stellant FLEX CT Injection System. This means you are not likely to find this item in a home medicine cabinet or a personal first-aid kit. Instead, it is specialized medical equipment used primarily within hospitals, imaging centers, and outpatient diagnostic facilities across the United States. The individuals most directly exposed to this hazard are the healthcare professionals who prepare and operate these systems, including radiologic technologists, nurses, pharmacists, and physicians who administer contrast media during Computed Tomography (CT) scans.
The core of the risk here stems from a manufacturing sterilization issue. If some of these syringe kits were not properly sterilized, they could introduce microorganisms into the patient’s body during the injection process. While modern healthcare facilities have rigorous protocols to minimize infection, a compromised sterile barrier on a device that penetrates or interfaces with the vascular system is a serious concern. The patients who are most vulnerable in this scenario are those undergoing CT scans who require intravenous contrast injections. These individuals often fall into specific high-risk categories for several reasons.
First, elderly patients are frequently among those requiring CT imaging due to age-related health conditions such as suspected strokes, internal bleeding, or cancer screenings. As people age, their immune systems naturally become less robust, a condition known as immunosenescence. This makes it harder for the body to fight off even minor bacterial introductions that might otherwise be cleared by a healthy immune response. For an elderly patient, what might be a manageable infection in a younger person could rapidly escalate into a severe systemic infection or sepsis.
Secondly, patients with compromised immune systems are at heightened risk. This includes individuals undergoing chemotherapy for cancer treatment, organ transplant recipients taking immunosuppressive drugs, or those with chronic conditions like diabetes or HIV/AIDS. Their bodies have reduced capacity to neutralize pathogens. If a non-sterile syringe kit is used in these cases, the threshold for developing an infection is significantly lower, and the consequences can be far more severe than for a healthy individual.
Additionally, patients with existing vascular access devices, such as central lines or ports, are more susceptible to infections entering through these entry points. The Stellant FLEX system is often used for precise delivery of contrast media in complex diagnostic procedures, sometimes involving patients with difficult venous access who may require more invasive or prolonged interventions. Any breach in sterility during such delicate procedures can lead to local site infections that may spread to the bloodstream.
It is also important to note that the risk is not limited to immediate reactions. Healthcare workers handling these kits are also at risk if they come into contact with contaminated surfaces, although their primary exposure would likely be through accidental needle sticks or cross-contamination during setup. Because the distribution pattern covers nationwide facilities in Pennsylvania and beyond, any healthcare provider working with Stellant FLEX CT Injection Systems should consider this group—both patients and staff—as those most potentially affected by this manufacturing defect.
How to tell if you have the recalled item
Identifying whether a specific piece of medical equipment is part of this FDA recall requires careful attention to several unique identifiers. Because this recall involves specialized medical hardware used in clinical settings—specifically the MEDRAD Stellant FLEX Syringe Kit designed for use with the Stellant FLEX CT Injection System—you are unlikely to encounter this product in a standard retail environment. Instead, you should look for specific technical markings on the device packaging or the unit itself if it is already installed or in storage at a healthcare facility.
The most reliable way to confirm if your item is affected is to check three distinct pieces of information: the catalog number, the Universal Device Identifier (UDI-DI), and the batch details. Start by locating the product label on the sterile packaging or the kit box. You are looking for the Catalog Number, which must read exactly FLEXS-150-QFT. This alphanumeric code is critical because it defines the specific configuration of the syringe kit. If the catalog number differs even slightly, the item may not be part of this specific recall action.
Next, verify the UDI-DI, which serves as a digital fingerprint for the device. On the label, locate the field marked UDI-DI and confirm that it reads 00616258022895. This long string of digits is assigned to this specific medical device model and is scanned in healthcare databases to track the product’s lifecycle. Matching this number exactly ensures you are looking at the correct hardware family.
Finally, because this recall stems from a manufacturing sterilization issue, it is limited to specific production runs rather than the entire global supply of Stellant FLEX kits. You must check the Affected Material Number and the Affected Batch Number. Look for the material number 87078825 and the batch number 8688750. These numbers are typically printed on the lot label of the sterile barrier system. If your kit has these specific batch identifiers, it falls within the scope of the recall initiated by Bayer Medical Care on July 31, 2026. Since the distribution pattern was nationwide across the United States, including Pennsylvania, any facility that received inventory during this period should perform this check immediately to ensure patient safety.
What to do — step by step
If you are a healthcare provider or facility administrator currently using the MEDRAD Stellant FLEX Syringe Kit in conjunction with the Stellant FLEX CT Injection System, your immediate priority is patient safety. Because this recall involves a potential sterilization failure, the risk of introducing pathogens into a patient’s body is real and serious. The FDA has classified this as a Class II recall, which indicates that use of the product may cause temporary or medically reversible harm to health, but in cases involving sterile medical devices, the consequences can be far more severe, including life-threatening infections. Therefore, you must treat this situation with urgency.
Step 1: Immediately Stop Using the Affected Kits
The very first action you must take is to remove any affected MEDRAD Stellant FLEX Syringe Kit (Catalog number FLEXS-150-QFT) from your inventory and cease its use for any patient procedures. Do not wait for confirmation of a specific unit’s status; if the kit falls under the distribution pattern described in the FDA notice, assume it is part of the recall batch until proven otherwise. The affected material number is 87078825 and the affected batch number is 8688750. By stopping use immediately, you prevent any potential exposure to non-sterile components. This is not a precautionary measure you can delay; it is a critical safety barrier.
Step 2: Quarantine the Affected Inventory
Once you have identified the kits within your facility, do not simply discard them in regular waste streams. Place them in a secure, isolated area designated for recalled medical devices. This quarantine step serves two purposes: it prevents accidental reuse by staff who may be unaware of the recall status, and it preserves the integrity of the product for potential investigation or remediation by Bayer Medical Care. Ensure that all personnel involved in radiology or interventional procedures are notified immediately about this quarantine to avoid any mix-ups during busy clinical hours.
Step 3: Contact Bayer Medical Care for Remediation Instructions
The official FDA recall notice does not explicitly state the specific remedy, such as whether you should return the items for a refund or if they will be replaced. However, standard protocol for Class II device recalls of this nature requires direct communication with the manufacturer to determine the correct disposal or exchange process. You must contact Bayer Medical Care directly to report your possession of the affected units. They will provide you with the specific instructions for returning the catalog number FLEXS-150-QFT kits (UDI-DI: 00616258022895) or arranging for their collection. Do not attempt to dispose of these devices in standard medical waste without explicit guidance from the manufacturer, as improper disposal could violate regulatory standards.
Step 4: Document Everything
Keep a detailed record of every affected unit you have identified, including batch numbers and material numbers. Document the date you stopped using them, the location where they are quarantined, and all communications with Bayer Medical Care. This documentation is vital for your facility’s compliance records and may be necessary if any adverse events occur or if regulatory bodies request proof of your response to the recall.
Step 5: Monitor for Adverse Events
If you have used any of these kits prior to identifying the recall, monitor patients closely for any signs of infection or other complications related to sterile technique failure. Report any such incidents to the FDA’s MedWatch program and notify Bayer Medical Care. Your vigilance here is crucial not only for patient care but also for helping regulatory agencies understand the full scope of this manufacturing issue.
Your refund, repair, or replacement options
When a medical device recall occurs, the most immediate question for healthcare providers and facility managers is often, "What do I do with the affected equipment?" In this specific instance involving Bayer Medical Care, Inc., the FDA classification is a Class II recall, which indicates a serious health hazard but one that is likely reversible or treatable if addressed correctly. However, there is a critical gap in the public record regarding the specific remedy for this recall. The official FDA documentation states that the remedy is "not stated." This absence of explicit instructions does not mean you are left without options, but it does mean you must proceed with caution and proactive communication rather than passive waiting.
Because the recall stems from a manufacturing sterilization issue, the primary concern is not that the device will fail mechanically, but that it may introduce pathogens into a patient's body. Therefore, the standard industry remedy for any medical device with a confirmed sterilization failure is immediate cessation of use. You should not attempt to "repair" or "re-sterilize" the MEDRAD Stellant FLEX Syringe Kit yourself. Attempting to clean or modify these devices could compromise their structural integrity and void any remaining liability protections. The only valid "repair" in this context is the manufacturer's validation that a new, properly sterilized unit has replaced the old one.
Since the specific remedy terms are not listed in the recall notice, you must contact Bayer Medical Care directly to determine the exact course of action. They will likely offer one of three standard outcomes: a full credit or refund for the purchased units, a direct replacement with a new kit that has passed sterilization verification, or a collection service where they retrieve the affected inventory from your facility. To initiate this process, you will need to have your specific catalog number (FLEXS-150-QFT), UDI-DI (00616258022895), and affected batch number (8688750) ready. These identifiers are crucial because the recall is limited to specific batches, meaning not every Stellant FLEX Syringe Kit you own is necessarily part of this problem.
It is also important to note that while the recall distribution was nationwide, the company is headquartered in Pennsylvania. If you are unable to reach Bayer’s general customer service line, checking their official website for a dedicated medical device quality or safety contact may yield faster results than general sales inquiries. Do not rely on third-party distributors to make the final call on whether a unit is safe to use; only the manufacturer can confirm if a specific batch has been cleared for release after remediation.
In summary, your immediate "option" is to quarantine any stock matching the affected material number (87078825) and batch number. Do not use them. Then, reach out to Bayer Medical Care to request their official recall action plan. Until they confirm in writing that a unit is safe or provide you with a replacement, assume it is unsafe for patient care.
What can happen if you ignore it
It is completely understandable to feel hesitant about stopping a medical procedure or discarding equipment that has been sitting in a supply room for months. You might be thinking that the syringe kits are still sealed, that they look pristine, and that the risk seems theoretical rather than immediate. However, ignoring a Class II medical device recall related to sterilization is not a minor oversight; it is a significant breach of the safety protocols designed to protect both patients and healthcare providers. The core issue here is not mechanical failure or incorrect dosage, but biological contamination. When a manufacturing sterilization process fails, the devices are left with viable microorganisms that were intended to be destroyed.
If you continue to use these MEDRAD Stellant FLEX Syringe Kits despite the recall notice, you are effectively bypassing the primary defense against infection in invasive medical procedures. The Stellant FLEX CT Injection System is used to deliver contrast media or other substances directly into a patient’s body during computed tomography scans. This often involves accessing veins or arterial lines, which creates a direct pathway for pathogens to enter the bloodstream. If the syringe kit was not properly sterilized, it may harbor bacteria, fungi, or spores that are invisible to the naked eye. Using such a device introduces these potential contaminants directly into the patient’s circulatory system.
The consequences of this exposure can range from mild local reactions to severe, life-threatening systemic infections. For a patient undergoing a CT scan, their immune system may already be compromised due to underlying illness, surgery, or age. Introducing non-sterile materials into such a vulnerable state can lead to localized infections at the injection site, characterized by redness, swelling, and pain. More dangerously, it can lead to bacteremia or sepsis, a body-wide inflammatory response to infection that can cause organ failure, shock, and death. Even in healthy individuals, introducing foreign biological contaminants into sterile tissue spaces can result in abscesses or other serious complications that require additional medical intervention, extended hospital stays, and potentially further surgeries to clean the infected area.
Furthermore, there is a professional and legal dimension to ignoring this recall. Healthcare facilities have a duty of care to ensure that all equipment used meets federal safety standards. Using recalled devices exposes providers and institutions to substantial liability if a patient suffers an adverse event. The FDA classifies this as a Class II recall because the products are not likely to cause serious adverse health consequences or death, but this classification assumes that the defect is identified and corrected promptly. By ignoring the notice, you remove the safety net that prevents those "unlikely" scenarios from becoming reality. The risk is not just about the syringe itself failing; it is about the silent, invisible threat of infection that can take days to manifest, making it difficult to trace back to the source if proper protocols are not followed.
Ultimately, the decision to ignore a sterilization recall trades short-term convenience for long-term health security. The peace of mind that comes from knowing every item touching your patient is sterile is invaluable. When that certainty is compromised by using a known defective product, the potential for harm shifts from theoretical to tangible. It is far easier and safer to replace the syringe kits now than to manage the complex medical and legal aftermath of an infection acquired through preventable means.